Newsletter

We are seeking to appoint a International Business Development Manager to build our international client portfolio. Your profile You have a proven record in sales/business development at a high level at the same type of company You are self-reliant, organised, curious, rigorous and tenacious – and you enjoy working in a team You have good management skills Fluency in both French and English is a non-negotiable requirement Type of employment contract : permanent contract (with probatory period) Place of work : Nancy (France) or Caen (France)

We are seeking to appoint a Sales Development Representative (SDR) to build our international client portfolio. Your profile You have previous experience in sales/business development, ideally in SDR or BDR You are self-reliant, organised, curious, rigorous and tenacious – and you enjoy working in a team Fluency in both French and English is a non-negotiable requirement Type of employment contract : permanent contract (with probatory period) Place of work : Nancy (north-eastern France, in the department of Meurthe et Moselle) For more details

Pour accompagner sa croissance, ETAP-Lab recrute. Investi·e et motivé·e, vous participerez à la préparation et la mise en œuvre d’expérimentations dans le domaine de la Neurologie et de la Dermatologie. Pré-requis : Bac+2 ou 3 en biologie : Bioanalyses et contrôles, Licence Génie moléculaire et cellulaire, … Type de contrat : CDD de 12 mois avec évolution possible vers un CDI Localisation : Nancy (54) Descriptif du poste  

A new research article resulting from a collaboration between the Institut de Cancérologie de Lorraine, bladder cancer company Photocure and ETAP-Lab was recently published in the journal Biomedicines: “Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer” >> Article This article reports on the effectiveness of a new therapy for the treatment of bladder cancer. By means of longitudinal follow-up over a period of up

The poster we presented at the Alzheimer’s Disease and Parkinson’s Disease conference is now available ; it’s all about our innovative in vitro and in vivo models of Alzheimer’s disease, which are based on the use of human A-Beta 1-42 oligomers. The poster focuses on the main results of the characterisation of the model in the aged mouse. This reproducible and translational model is a new tool for the evaluation of compounds targeting the early stages of Alzheimer’s disease. We are very

Dr. Ahmad Allouche (Head of In Vitro Biology at ETAP-Lab) is co-author of the article: “Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease” published in the journal Glia. Conducted in collaboration with Dr. @Manuel Buttini from Luxembourg (National Center of Pathology), this work shows that, in the early induction stages of the Parkinson's disease process, diffusible alpha-synuclein oligomers spreeding is responsible for neurodegeneration and neuroinflammation. This induces microglia activation, prior to

ETAP-Lab est à la recherche d’un(e) « PROSPECTEUR(TRICE) COMMERCIAL(E)». Pour accompagner sa croissance à l’international, ETAP-Lab recrute. Vous aimez les challenges ?  Participez au développement commercial de notre entreprise ! Pré-requis : Bac+2/+3, avec une double compétence en biologie. Type de contrat : CDD de 6 mois avec évolution possible vers un CDI Localisation : Nancy (54)

Discover ETAP-Lab and other biotech businesses at an Afterwork evening on November 18th, organised by Biovalley France. Nicolas Violle will be delighted to meet you and tell you about what we do at ETAP-Lab. A rare opportunity to connect with key players in the Lorraine region. Thanks to BioValley France for making it happen! https://www.biovalley-france.com/fr/agenda/les-biotechs-du-coin-un-afterwork-dedie-au-foyer-lorrain/

Hypo-excitability was reported in the peri-infarct tissue following stroke, an effect counteracted by a blockage of α5-GABAA receptors in adult rodents. Our present study aims to evaluate the effect of a selective α5-GABAA receptor antagonist, S 44819, in stroke in juvenile animals. We have set up and characterized an original model of transient ischemic stroke in 28 day-old Sprague-Dawley rats (45-min occlusion of the middle cerebral artery by intraluminal suture). In this model, S 44819 (1, 3 and 10 mg/kg,